Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study (Q34100788)

31 July 2017

title

Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study (English)

1 reference

31 July 2017

main subject

cardiovascular disease

1 reference

Jui-Ming Chen

1

1 reference

31 July 2017

Cheng-Wei Chang

2

1 reference

31 July 2017

Ying-Chieh Lin

3

1 reference

31 July 2017

Jorng-Tzong Horng

4

1 reference

31 July 2017

Wayne H-H Sheu

5

1 reference

31 July 2017

publication date

7 July 2014

1 reference

Journal of Diabetes Research

31 July 2017

published in

1 reference

31 July 2017

volume

2014

1 reference

31 July 2017

page(s)

812628

1 reference

Creative Commons Attribution 3.0 Unported

31 July 2017

copyright license

start time

1 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: An Asian-Pacific perspective and expert recommendations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Postprandial hyperglycemia and glycemic variability: should we care?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Pharmacology of alpha-glucosidase inhibition.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study

5 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Significance of testing platelet functions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

The alpha (α)-glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow responses to intraduodenal sucrose in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Acarbose reduces myocardial infarct size by preventing postprandial hyperglycemia and hydroxyl radical production and opening mitochondrial KATP channels in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F812628

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4147291

Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance

28 October 2018

1 reference

12 December 2020

Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes

1 reference

12 December 2020

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

1 reference

12 December 2020

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

Identifiers

DOI

10.1155/2014/812628

1 reference

31 July 2017

1 reference

31 July 2017

1 reference